CDKN2A and neoplasm: The 20 tumor sections selected included ten from G500 heterozygotes typed with loss of p16INK4a gene dosage using the multiplex PCR analysis and ten tumors from C500 homozygotes typed with no loss in p16INK4a gene dosage by multiplex PCR analysis.